10 June 2026 | Wednesday | News
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology.
The first shoulder arthroplasty cases using CORI XT Platform were performed at Duke Health by a surgical team led by Dr. Christopher Klifto. Dr. Klifto utilized CORI◊ SHOULDER Handheld Robotic Arthroplasty in combination with the AETOS◊ Shoulder System. CORI SHOULDER offers a complete robotic procedure, supporting handheld robotic execution of the humerus and glenoid, across both anatomic and reverse procedures.
Dr. Klifto said, “The CORI SHOULDER workflow was streamlined and efficient; registration and planning were seamless; and the post‑op x‑rays matched our pre‑op planning. A proud moment for the team and an exciting milestone for shoulder robotics.”
Building on this initial clinical experience, Dr. Bertrand Kaper completed the first CORI XT shoulder arthroplasty cases in an ambulatory surgery center (ASC) setting at North Valley Surgery Center in Scottsdale, Arizona, further expanding the use of CORI XT Platform across care environments, and highlighting the versatility and fit of the CORI XT Platform in an ASC setting, and the well-suited nature of handheld robotics to shoulder arthroplasty.
Reflecting on these first cases, Dr. Kaper said, “It is a privilege to be part of this transformative effort to bring the accuracy of robotic technology to the surgical treatment of shoulder arthritis. The use of CORI Handheld Robotics allows us to merge advanced technology with surgical expertise to deliver personalized care for shoulder surgery. As we have witnessed with our knee replacement patients, robotic technology enhances the potential for patient recovery and implant longevity. I am confident that these innovations will become the standard for helping our patients who are dealing with the pain and disability of shoulder arthritis.”
© 2026 Biopharma Boardroom. All Rights Reserved.